loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Tepotinib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Tepotinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients

    07 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220907005443/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    Merck Europe B.V. Tepmetko(tepotinib) Receives Approval in Europe
    Merck Europe B.V. Tepmetko(tepotinib) Receives Approval in Europe

    05 May 2022

    // EMA

    https://www.ema.europa.eu/en/documents/overview/tepmetko-epar-medicine-overview_en.pdf

    EMA
    05 May 2022
    Share Share
    EC Approves TEPMETKO in Advanced NSCLC with METex14 Skipping Alterations
    EC Approves TEPMETKO in Advanced NSCLC with METex14 Skipping Alterations

    18 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220217005798/en

    BUSINESSWIRE
    18 Feb 2022
    Share Share
    TEPMETKO Receives Positive CHMP Opinion in Advanced NSCLC
    TEPMETKO Receives Positive CHMP Opinion in Advanced NSCLC

    17 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211216005685/en

    BUSINESSWIRE
    17 Dec 2021
    Share Share
    MHRA backs Merck’s MET inhibitor Tepmetko
    MHRA backs Merck’s MET inhibitor Tepmetko

    13 Oct 2021

    // Lucy Parsons PHARMATIMES

    https://www.pharmatimes.com/news/mhra_backs_mercks_met_inhibitor_tepmetko_1380739

    Lucy Parsons PHARMATIMES
    13 Oct 2021
    Share Share
    EMD Serono to Highlights From Oncology Portfolio at WCLC & ESMO 2021
    EMD Serono to Highlights From Oncology Portfolio at WCLC & ESMO 2021

    13 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210912005053/en

    BUSINESSWIRE
    13 Sep 2021
    Share Share